Brabant Pharma
http://www.brabantpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Brabant Pharma
Start-Up Quarterly Statistics, Q4 2014
In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.
Biopharma Quarterly Dealmaking Statistics, Q4 2014
Biopharma financing increased 53% in Q4 to $8.8 billion; Actavis’ $65 billion takeover of Allergan topped the M&A activity, and Janssen led in dealmaking with six alliances.
Deals Shaping The Medical Industry, December 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
Deal Watch: Bristol Adds To Oncology Pipeline With F-star Alpha Option Pact
Novartis completes the divestiture of its vaccines business by selling off two influenza vaccines to Australia’s CSL Ltd. Zogenix buys out Britain’s Brabant pharma and Pain Therapeutics is searching for a new partner for Remoxy after Pfizer drops the abuse-deterrent opioid.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice